NCT02323334View on ClinicalTrials.gov

A Study of LY3202626 in Healthy Participants and Participants With Alzheimer's Disease

PHASE1CompletedINTERVENTIONAL
Enrollment

94

Participants

Timeline

Start Date

December 31, 2014

Primary Completion Date

February 29, 2016

Study Completion Date

February 29, 2016

Conditions
Healthy VolunteersAlzheimer Disease
Interventions
DRUG

LY3202626

administered orally

DRUG

Placebo (Part A, B, C)

administered orally

DRUG

Itraconazole

administered orally

Trial Locations (1)

91206

California Clinical Trials Medical Group, Glendale

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT02323334 - A Study of LY3202626 in Healthy Participants and Participants With Alzheimer's Disease | Biotech Hunter | Biotech Hunter